Sees FY23 revenue $730M – $750M, consensus $732.49M.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on MYGN:
- Myriad Genetics Reports First Quarter 2023 Financial Results; Achieves 10% Revenue Growth Year-Over-Year, the Second Consecutive Quarter of Double-Digit Year-Over-Year Revenue Growth; Raises Mid-Point of 2023 Revenue Guidance Range
- Myriad Genetics to Participate in BofA Securities Healthcare Conference
- Myriad Genetics to Release First Quarter Financial Results on May 3, 2023
- 77% of Americans have used addictive behaviors or unhealthy coping mechanisms to manage their mental health, according to Myriad Genetics nationwide survey
- Myriad, Intermountain Precision now offer solid tumor testing in all states